ArticleClinical genitourinary cancer2018
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Article in Clinical genitourinary cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Interpretable machine learning for cardiovascular disease risk prediction in cancer survivors: development and internal validation.Cardio-oncology (London, England) · 2026Article
- Exercise, diet and psychological support for patients with testicular cancer.Nature reviews. Urology · 2026Review
- Increased cardiovascular risk among cancer survivors presenting with chest pain.European heart journal open · 2025Article
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Cardiovascular toxicity in testicular germ cell tumor survivors.Frontiers in oncology · 2025Review
- Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults.Current epidemiology reports · 2023Article
- Habitual physical activity modulates cardiometabolic health in long-term testicular cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment.Current oncology reports · 2023Review
- Cancer history as a predictor in cardiovascular risk scores: a primary care cohort study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Article
- Polygenic Health Index, General Health, and Pleiotropy: Sibling Analysis and Disease Risk Reduction.Scientific reports · 2022Article
- Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors After Cisplatin-Based Chemotherapy.JNCI cancer spectrum · 2022Article
- Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer.Cardio-oncology (London, England) · 2021Review
- Ten-year cardiovascular risk among cancer survivors: The National Health and Nutrition Examination Survey.PloS one · 2021Article
- Long-term Testis Cancer Survivors in Canada-Mortality Risks in a Large Population-based Cohort.European urology open science · 2020Article
- [Long-term effects of cisplatin-based chemotherapy in testicular cancer patients-what is important?]Der Urologe. Ausg. A · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundTesticular cancer survivors (TCSs) are at increased risk of cardiovascular disease (CVD) after cisplatin-based chemotherapy (CBCT). Identifying at-risk survivors would allow early intervention, but risk prediction tools such as the Framingham Risk Score (FRS) have not been applied to TCSs given modern chemotherapy.
methodsTCSs > 1 year post-CBCT were evaluated. Associations between FRS and clinical, socioeconomic, and lifestyle measures and treatment regimen (4 cycles, etoposide and cisplatin [EP × 4]); 3 or 4 cycles, bleomycin plus EP (BEP × 3, BEP × 4) were analyzed with general linear multivariable models. Controls from the National Health and Nutrition Examination Survey were matched 1:1 to TCSs by age, race, and education with differences in mean FRS evaluated with 2-sided t tests.
resultsOf 787 TCSs (median age, 37.3 years; median follow-up, 4.2 years), 284, 342, and 161 received EP × 4, BEP × 3, or BEP × 4, respectively. TCSs had higher median systolic blood pressure (126 vs. 119 mm Hg; P < .001), but fewer were smokers (8.4% vs. 28.2%; P < .001) than controls. In multivariable analysis, no significant differences in FRS between EP × 4, BEP × 3, and BEP × 4 were observed, but less than college education (P < .001) and lack of vigorous exercise (P = .006) were associated with higher FRS. Mean FRS did not differ between TCSs and controls (6.8% vs. 7.3%; P = .67).
conclusionThis is the first study to apply the office-based FRS to TCSs. Chemotherapy regimen (BEP × 3 vs. EP × 4) was not associated with FRS, but less educated and less vigorously active patients had higher FRS, and present a high-risk subgroup for intense follow-up and counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.